Boehringer Ingelheim USA Corporation

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Tolerability and Pharmacokinetics of Lacidipine With and Without the Co-administration of Telmisartan in Female and Male Healthy Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Lacidipine
Drug: Telmisartan

First Posted Date: 2014-07-30

Last Posted Date: 2014-08-06

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 26

Registration Number: NCT02203500

Effect of Repeated Doses of BI 1060469 and BI 1021958 on Glomerular Filtration Rate (GFR) in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Placebo
Drug: Cimetidine
Drug: Naproxen
Drug: BI 1060469 high dose
Drug: BI 1060469 low dose
Drug: BI 1021958

First Posted Date: 2014-07-29

Last Posted Date: 2014-12-24

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 53

Registration Number: NCT02202512

Locations: 🇩🇪
1333.43.1 Boehringer Ingelheim Investigational Site, Berlin, Germany

Evolution of Pulse Pressure Following Initiation of Antihypertensive Therapy in Patients With Essential Arterial Hypertension

Completed

Conditions: Hypertension

Interventions: Drug: Micardis®
Drug: Other hypertensives

First Posted Date: 2014-07-29

Last Posted Date: 2014-07-29

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 2148

Registration Number: NCT02202525

Volasertib in Combination With Azacitidine in Japanese Patients With Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia

Phase 1

Completed

Conditions: Myelodysplastic Syndromes
Leukemia, Myelomonocytic, Chronic

Interventions: Drug: Azacitidine
Drug: Volasertib

First Posted Date: 2014-07-28

Last Posted Date: 2018-07-30

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 5

Registration Number: NCT02201329

Locations: 🇯🇵
Boehringer Ingelheim Investigational Site, Tokyo, Sinagawa-ku, Japan

Dose-escalation Study of BIBH 1 in Patients With Non-small Cell Lung Cancer Scheduled for Surgical Resection

Phase 1

Terminated

Conditions: Lung Neoplasms

Interventions: Drug: BIBH 1

First Posted Date: 2014-07-25

Last Posted Date: 2014-07-25

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 6

Registration Number: NCT02199886

A Trial Comparing MICARDIS® (Telmisartan) and COZAAR® (Losartan) in Patients With Mild-to-Moderate Hypertension Using Ambulatory Blood Pressure Monitoring (ABPM)

Phase 4

Completed

Conditions: Hypertension

Interventions: Drug: Low dose of Micardis®, once daily
Drug: Low dose of COZAAR®, once daily
Drug: High dose of Micardis®, once daily
Drug: High dose of COZAAR®, once daily
Drug: Placebo

First Posted Date: 2014-07-25

Last Posted Date: 2014-07-25

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 333

Registration Number: NCT02200640

Pharmacovigilance and Patient Compliance in Hypertensive Patients

Completed

Conditions: Hypertension

Interventions: Drug: Telmisartan

First Posted Date: 2014-07-25

Last Posted Date: 2014-07-25

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 10333

Registration Number: NCT02200575

Single Rising Dose Study Investigating the Safety, Tolerability and Pharmacokinetics of Spray Dried BIBN 4096 BS After Inhalation Administration in Healthy Male and Female Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: SD I
Drug: SD II
Drug: Placebo

First Posted Date: 2014-07-25

Last Posted Date: 2014-07-25

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 63

Registration Number: NCT02199860

Evaluation of the Effects of Pharmaton Tablets on Mental Performance and Physical Fatigue in Nurses Working Night Shift

Phase 2

Completed

Conditions: Sleep Disorders, Circadian Rhythm

Interventions: Drug: Placebo
Drug: Pharmaton® Caplets

First Posted Date: 2014-07-25

Last Posted Date: 2014-07-25

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 32

Registration Number: NCT02199847

Safety, Tolerability and Pharmacodynamics of BIIX 1 XX in Healthy Young Male Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Placebo
Drug: BIIX 1 XX - single rising dose

First Posted Date: 2014-07-25

Last Posted Date: 2014-10-29

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 24

Registration Number: NCT02199873

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy